ArticleDie Ophthalmologie2026
[Transient maculopathy after intracameral injection of cefuroxime].
Article in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report on two cases of transient maculopathy following uneventful cataract surgery with intracameral administration of cefuroxime. Both patients achieved a visual acuity of no more than 20/200 on day 1 after surgery. Optical coherence tomography revealed a neurosensory detachment of the retina with schisis-like alterations in the outer nuclear layer. These findings completely resolved within 6 days of treatment with prednisolone acetate and nepafenac eye drops, resulting in full visual recovery.Intracameral administration of antibiotics, in Europe as cefuroxime 1 mg/0.1 ml, is recommended for endophthalmitis prophylaxis at the end of cataract surgery. At the same time, an association appears to exist between the rare occurrence of specific maculopathies and the application of cefuroxime, particularly in cases of overdose, but also sporadically. Patients who have undergone pars plana or anterior vitrectomy apparently have an inherently higher risk of developing maculopathy. Transient cefuroxime maculopathy usually has a benign, self-limiting course. Cataract surgeons should be aware of this condition and avoid overdosing that otherwise safe and effective drug.
Indexed as
Identifiers
41296048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.